arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

MapLight Therapeutics, Inc.

MPLT
$12.17 ▼ -1.11 (-8.36%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

MapLight Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $105.6M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -29.1%
FCF / Share $-15.97
Trailing P/E
Price / Book 1.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-161.15M
↓ -107.7%
FCF / Share Free cash flow per share
$-15.97
↑ +85.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
21
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 10 quarters